Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (841-850 of 1,123) with videos related to

Pageof 113
Sort By:
British Journal of Clinical Pharmacology|March 26, 2018
A pharmacological rationale for improved everolimus dosing in oncology and transplant patientsR Ter Heine, N P van Erp, H J Guchelaar, et al.
British Journal of Clinical Pharmacology|January 29, 2021
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costsMendy Ter Avest, Saskia M C Langemeijer, Saskia E M Schols, et al.
AIDS (London, England)|September 16, 2022
Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara AfricaHylke Waalewijn, Kim Stol, Linda van der Knaap, et al.
HIV Medicine|March 28, 2008
Steady-state nevirapine plasma concentrations are influenced by pregnancyJ F J B Nellen, M Damming, M H Godfried, et al.
Clinical Pharmacology and Therapeutics|April 17, 2020
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen SusceptibilityEmilie M Gieling, Eveline Wallenburg, Tim Frenzel, et al.
Journal of Clinical Pharmacology|July 20, 2016
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy SubjectsLi Zhu, Roger J Brüggemann, Jonathan Uy, et al.
The Lancet. HIV|July 21, 2022
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studiesTom G Jacobs, Stef Schouwenburg, Martina Penazzato, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 17, 2010
Drug-drug interactions between raltegravir and pravastatin in healthy volunteersMatthijs van Luin, Angela Colbers, Eleonora W J van Ewijk-Beneken Kolmer, et al.
AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.
Antiviral Therapy|June 22, 2001
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trialN A Foudraine, S Jurriaans, G J Weverling, et al.
Pageof 113

Showing results (841-850 of 1,123) with videos related to

Sort By:
Pageof 113
British Journal of Clinical Pharmacology|March 26, 2018
A pharmacological rationale for improved everolimus dosing in oncology and transplant patientsR Ter Heine, N P van Erp, H J Guchelaar, et al.
British Journal of Clinical Pharmacology|January 29, 2021
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costsMendy Ter Avest, Saskia M C Langemeijer, Saskia E M Schols, et al.
AIDS (London, England)|September 16, 2022
Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara AfricaHylke Waalewijn, Kim Stol, Linda van der Knaap, et al.
HIV Medicine|March 28, 2008
Steady-state nevirapine plasma concentrations are influenced by pregnancyJ F J B Nellen, M Damming, M H Godfried, et al.
Clinical Pharmacology and Therapeutics|April 17, 2020
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen SusceptibilityEmilie M Gieling, Eveline Wallenburg, Tim Frenzel, et al.
Journal of Clinical Pharmacology|July 20, 2016
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy SubjectsLi Zhu, Roger J Brüggemann, Jonathan Uy, et al.
The Lancet. HIV|July 21, 2022
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studiesTom G Jacobs, Stef Schouwenburg, Martina Penazzato, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 17, 2010
Drug-drug interactions between raltegravir and pravastatin in healthy volunteersMatthijs van Luin, Angela Colbers, Eleonora W J van Ewijk-Beneken Kolmer, et al.
AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.
Antiviral Therapy|June 22, 2001
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trialN A Foudraine, S Jurriaans, G J Weverling, et al.
Pageof 113